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Summary
Hintergrund: In Anbetracht einer älter werdenden Bevöl-
kerung steigt die Häufigkeit sowohl kardialer als auch
tumorbedingter Erkrankungen. Problematisch wird es,
wenn eine Strahlenbehandlung in anatomischer Nähe
eines implantierten Schrittmachers mit integrierter Defi-
brillatorfunktion erfolgen muss. Diese hochpräzisen Ag-
gregate können auf ionisierende Strahlung mit Funk-
tionsverlust oder unkontrollierter Stimulation reagieren.
Beides kann lebensbedrohlich sein. Verfügbare Richtli-
nien empfehlen, dass am Schrittmacher eine Dosis von 
kumulativ 2 Gy nicht überschritten werden soll. Bei den
meisten Patienten, die sich einer Strahlenbehandlung im
Kopf-Hals-Bereich unterziehen, wird diese Dosis über-
schritten, was eine Explantation und das Tragen eines
externen Schrittmachers bzw. Defibrillators notwendig
machen würde. Fallbericht: Einem Patienten mit Larynx-
karzinom-Rezidiv wurde wegen schwerer kardialer Vor-
erkrankungen ein Schrittmacher mit Defibrillatorfunktion
implantiert. Die postoperative Strahlendosis an der Rezi-
divregion betrug 60 Gy, an den Lymphknoten 50 Gy. Im
Vorfeld wurde die Strahlenbelastung am Aggregat mit
2,5 Gy berechnet und in vivo mittels Thermolumines-
zenzmessungen verifiziert. Während der Bestrahlungs-
sitzungen wurde der Defibrillator extern deaktiviert. Re-
gelmäßige Aggregatkontrollen zeigten keinen Geräte-
defekt. Schlussfolgerung: Obwohl die Gesamtdosis von 
2 Gy am Schrittmacher und Defibrillator überschritten
wurde, zeigte das Aggregat während und nach der Strah-
lentherapie eine regelrechte Funktion.
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Summary
Background: Due to an aging population the incidence
of both cardiac and tumor-related illnesses is increasing.
A problem may arise if radiotherapy is necessary in close
anatomic proximity to an implantable cardioverter-defib-
rillator (ICD). These highly precise devices may respond
to ionizing radiation with a loss of function or uncon-
trolled stimulation, with both effects being potentially life
threatening. Available guidelines recommend the dose
maximum to a pacemaker to be cumulative below 2 Gy.
For most patients undergoing radiation therapy of the
neck or of the chest this limit is exceeded, thus making a
removal of the device and an implantation of an external
ICD necessary. Case Report: A patient with severe car-
diac problems underwent an implantation of an ICD.
However, a recurrence of a laryngeal cancer was diag-
nosed. The irradiation dose after resection was 60 Gy to
the tumor region and 50 Gy to the lymph nodes. Irradia-
tion peakload to the ICD was calculated to be 2.5 Gy. This
dose was verified with thermoluminescence measure-
ments. The ICD was externally deactivated during the
sessions of irradiation. Device checks demonstrated no
malfunction. Conclusion: Even though the dose limits of
the ICD of 2 Gy were exceeded, the device demonstrated
a regular function during and after radiotherapy.
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Introduction
In patients with cancers of the neck or chest region problems
may arise when the patient carries an implantable cardiovert-
er-defibrillator (ICD) or cardiac pacemaker when undergoing
radiation therapy. This concomitant occurrence of an ICD and
an indication for radiation therapy to the respective region has
not been frequently observed yet; however, an increase is ex-
pected due to an aging population and due to advances in
medical technology. Currently, the clinical experience with
these cases is very limited. While the first generation of pace-
makers was more resistant to ionizing radiation, the newer
ICD devices are more sophisticated and demonstrate a higher
precision. These more novel devices are significantly more
vulnerable to the effects of ionizing rays on the semiconductor
material or to electromagnetic interferences [1, 2]. Malfunc-
tion, however, can be dangerous and potentially life threaten-
ing for the patient. Very cautious recommendations were is-
sued by the American Society for Therapeutic Radiology and
Oncology (ASTRO) in 1990 [3] and by the American Associa-
tion of Physicists in Medicine (AAPM) in 1994 [4]. The accu-
mulated dose to a pacemaker was recommended not to ex-
ceed 2 Gy. However, for most patients with an ICD in a typi-
cal location this limit is readily exceeded, thus necessitating a
removal of the device and an external ICD prior to radiation
therapy. These guidelines, however, are well over 10 years old
and only based on the experience with the usually more sim-
plistic older pacemakers. Currently, new generations of ICD
are being used. In addition, efforts are made by radiation on-
cologists to escalate radiation dose to achieve higher cure
rates. The information provided by the manufacturers of the
devices is usually not helpful in this respect. They are very
cautious about maximum applicable irradiation doses for an
ICD due to the fear of claims for compensation. 
We report the case of a patient in whom the dose limit to an
implanted ICD was exceeded and demonstrate our medical
and technical management. 
Case Report
An extended local recurrence of a laryngeal cancer was diagnosed in a 
67-year-old man. Staging demonstrated a pT4 pN2b tumor. For the past
25 years the patient had also experienced severe cardiac problems making
the implantation of an ICD necessary. A DDD-RD St. Jude Medical
Atlas DR was implanted. 
We created a 3D multifield plan. An added dose-volume histogram
(DVH) was created for the ICD (fig. 1). Despite all efforts it was impossi-
ble to reduce the expected radiation to the ICD to less than a cumulative
dose of 2.5 Gy due to the close proximity to the tumor region. Irradiation
was administered conventionally 5 days a week with a multileaf linear
accelerator and 6 MV photons from January 2005 until March 2005. A 
4-field technique was applied. The extended tumor and lymphatic regions
were irradiated up to 36 Gy. Subsequently, we used a preserving tech-
nique for the spinal cord for an additional dose of 14 Gy. Only the former
tumor region was further treated with single doses of 2.0 Gy up to a dose
of 10.0 Gy. A cumulative dose of 60.0 Gy was achieved. 
We placed a magnet measuring 2.0 × 5.0 cm onto the ICD for deactivating
the device directly prior to the irradiation sessions. The patient was con-
nected to an ECG unit, which was monitored from the control room. A
radiation oncologist was present at all times in case of an emergency to re-
move the magnet from the ICD. This step could reactivate the ICD. On
the first day of radiation therapy we performed thermoluminescence (TL)
measurements in order to control for scattered radiation in vivo. Single
dosimeters were grouped around the ICD after it had been marked with
colors. Photographs of the single dosimeters were taken for the purpose of
easier classification of data (fig. 2). These measurements were taken as a
base for calculating the radiation for the extended field. Later, a second
TL measurement was carried out. This measurement was representative
for the field reduction. Additionally, the patient underwent cardiologic
checkups on a regular basis.
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Fig. 1. The pretreatment added dose distribution shows that the defibril-
lator received a maximum dose of 2.5 Gy. DVH = Dose-volume his-
togram.
 
Fig. 2. The implantable cardioverter-defibrillator is under the marked cir-
cle. The numbers show the thermoluminescence dosimeters. The field
margin from the lymphatical region reaches approximately to the lower
margin of the tracheal bandage.
It was possible to administer the radiation therapy without interruption or
complications. 5 cGy scattered radiation was measured in the center of the
ICD for one irradiation treatment. 9 cGy was measured on the ventral
and lateral margin of the ICD. The second measurement after field reduc-
tion showed 3 cGy centrally. The margins demonstrated ranges between 
5 and 7 cGy. In total, this resulted in a cumulative dose of 2.5 Gy on the
ICD for the whole treatment period. The measured TL doses correspond-
ed with the DVH calculated before starting treatment. All cardiologic ex-
aminations demonstrated a regular function of the ICD. At the final car-
diologic examination, ventricular fibrillation was intentionally induced.
The ICD terminated the dysfunction through internal shock with regular
charging time. The battery status was in order.
Discussion
An increase of patients with ICD and simultaneous cancer of
the head and neck region requiring radiotherapy is to be ex-
pected due to an aging population and due to advances in
medical technology. ASTRO [3, 5] and AAPM [4] guidelines
are, however, not based on experiences with newer generation
ICD devices. The cautious instructions of ASTRO, namely the
temporary or permanent removal of the ICD when exceeding
2 Gy, are considered as being too conservative by some au-
thors. Previous reports demonstrated that ICD devices of dif-
ferent manufacturers react differently to irradiation. The ad-
ministration of high single doses showed that at least 14 Gy
could be administered before dysfunction of the ICD [6–8].
Different single and total doses were tested in a water-equiva-
lent phantom with 18 MV photons. Irradiation was adminis-
tered from 0.05 Gy up to 8.0 Gy in single doses reaching 
200.0 Gy in total dose. There was a wide range of serious mal-
functions. One device was seriously damaged after 0.15 Gy,
whereas 10 other devices were treated with over 140.0 Gy
without malfunction [3, 9].
Malfunctions of the device can be life threatening for the pa-
tient because of reduced reliability to deliver a shock, if need-
ed, or because of uncontrolled shock triggering. The high de-
gree of uncertainty in the treatment of patients with pace-
makers or ICD was shown in a representative multicenter
study at 75 radiooncological departments in the USA and
Canada [10].
A dose of up to 2 Gy on the cardiac pacemaker or 1 Gy on the
defibrillator is generally considered safe. According to our
own experience, however, 1 Gy at an ICD in a typical location
is readily exceeded when irradiating a cancer of the neck or
chest region. 
Since no official guidelines are available for ICD and the pre-
diction of the device’s sensitivity to irradiation shows a large
variation, we suggest the following proceeding: 
The ICD should be outside the irradiation field. Prior to the
treatment the estimated scattered radiation dose should be
calculated and the risk of an ICD malfunction should be clear-
ly documented in the patient’s informed consent, as it is im-
possible to assess the exact individual risk. The device should
be deactivated with a magnet during irradiation. The patient
should be monitored with an ECG unit and a physician should
be present in case of an emergency. In vivo dosimetric mea-
surements should be performed on the first day of irradiation
in order to document scattered radiation. ICD checkup should
be performed during the treatment period and thereafter. In
our case a total of 2.5 Gy was tolerated without complications.
We were thereby able to avoid a removal of the ICD in the re-
ported case by moderate medical and technical efforts.
Conclusion
In our case, a patient with an ICD underwent radiotherapy
of a head and neck tumor without complications even
though 2 Gy were exceeded. No standard protocols are cur-
rently available for the new generations of ICD. Since the
exact evaluation of the individual risk prior to radiotherapy
is not possible, special precautions are necessary. We ob-
served no complications during therapy when adhering to
the proceedings proposed in this report with moderate addi-
tional effort. We would, however, recommend treatment
only at facilities with cardiologic units. We are aware that
ours is a single patient experience, but it nevertheless ap-
pears to be a practicable option. 
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